PYC Therapeutics Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Public

  • Employees
  • 25

Employees

  • Stock Symbol
  • PYC

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.85
  • (As of Tuesday Closing)

PYC Therapeutics General Information

Description

PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.

Contact Information

Website
www.pyctx.com
Formerly Known As
Phylogica, Ltd., Phylogica Limited, Phylogica
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • The Esplanade Mount Pleasant
  • Suite 7, 8
  • Nedlands, Western Australia 6153
  • Australia
+61 (08)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
ASX
Vertical(s)
Life Sciences
Corporate Office
  • The Esplanade Mount Pleasant
  • Suite 7, 8
  • Nedlands, Western Australia 6153
  • Australia
+61 (08)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PYC Therapeutics Stock Performance

As of 25-Mar-2025, PYC Therapeutics’s stock price is $0.85. Its current market cap is $467M with 551M shares.

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.85 $0.84 $0.53 - $1.39 $467M 551M 462K -$0.07

PYC Therapeutics Financials Summary

As of 31-Dec-2024, PYC Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 30-Jun-2024 FY 2023 30-Jun-2023 FY 2022 30-Jun-2022
EV 353,288 355,960 117,004 123,441
EBITDA (32,684) (25,071) (15,368) (9,744)
Net Income (31,792) (24,723) (15,321) (10,046)
Total Assets 42,425 60,984 24,601 31,198
Total Debt 752 744 209 649
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PYC Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PYC Therapeutics‘s full profile, request access.

Request a free trial

PYC Therapeutics Patents

  • 220

    Total Documents Applications and Grants

  • Total Patents Families

  • 42

    Granted

  • 52

    Pending

  • Expiring in next 12 mo

PYC Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025900540-A0 Gene-mediated conditions Pending 25-Feb-2025
AU-2024903714-A0 Improved compositions and methods for treatment of monogenic neurodevelopmental disorders 8 Pending 13-Nov-2024
AU-2024903650-A0 Compositions and methods for treatment of kidney disease Pending 08-Nov-2024
AU-2024902223-A0 Improved compositions and methods for treatment of monogenic neurodevelopmental disorders 7 Pending 17-Jul-2024
AU-2024901708-A0 Improved compositions and methods for treatment of monogenic neurodevelopmental disorders 6 Pending 06-Jun-2024
To view PYC Therapeutics’s complete patent history, request access »

PYC Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PYC Therapeutics Investments (2)

PYC Therapeutics’s most recent deal was a Secondary Transaction - Private with Vision Pharma for . The deal was made on 13-Mar-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Vision Pharma 13-Mar-2022 Secondary Transaction - Private Pharmaceuticals
Vision Pharma 01-Oct-2019 Joint Venture Pharmaceuticals
To view PYC Therapeutics’s complete investments history, request access »

PYC Therapeutics FAQs

  • When was PYC Therapeutics founded?

    PYC Therapeutics was founded in 2001.

  • Where is PYC Therapeutics headquartered?

    PYC Therapeutics is headquartered in Nedlands, Australia.

  • What is the size of PYC Therapeutics?

    PYC Therapeutics has 25 total employees.

  • What industry is PYC Therapeutics in?

    PYC Therapeutics’s primary industry is Drug Discovery.

  • Is PYC Therapeutics a private or public company?

    PYC Therapeutics is a Public company.

  • What is PYC Therapeutics’s stock symbol?

    The ticker symbol for PYC Therapeutics is PYC.

  • What is the current stock price of PYC Therapeutics?

    As of 25-Mar-2025 the stock price of PYC Therapeutics is $0.85.

  • What is the current market cap of PYC Therapeutics?

    The current market capitalization of PYC Therapeutics is $467M.

  • What is PYC Therapeutics’s annual earnings per share (EPS)?

    PYC Therapeutics’s EPS for 12 months was -$0.07.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »